Our findings underscore the relationship between m6A and the tumor immune environment, particularly highlighting the interaction of our identified MPIGs—specifically TNFRSF6B, CXCL2, PSMD2, VEGFC, GRB2, CMTM1, CBL, CYR61, SDC1, and CTSE—with upstream m6A regulators, primarily METTL3 and VIRMA, significantly affecting UC progression. Here, VIRMA is linked to neoplasm.